Undisclosed MYC c-mod
/ Dewpoint Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 14, 2025
Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025
(GlobeNewswire)
- "Oral condensate modulators (c-mods) demonstrate efficient and selective killing of cancer cells in multiple pre-clinical models of MYC-driven cancers."
Preclinical • Solid Tumor
September 10, 2025
Dewpoint Therapeutics…announced the closing of its Series D financing to advance DPTX3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end 2025 and deliver early clinical proof-of-concept by the end of 2026
(GlobeNewswire)
- "It will also accelerate development of Dewpoint’s first-in-class c-mod targeting MYC...while strengthening ongoing collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma. The financing provides operational runway into early 2027."
Financing • New trial • Gastric Cancer • Ovarian Cancer
March 26, 2025
Dewpoint Therapeutics announces upcoming presentations at AACR 2025
(GlobeNewswire)
- "Dewpoint will present two posters at AACR; Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer; C-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin."
Preclinical • Oncology • Ovarian Cancer
1 to 3
Of
3
Go to page
1